Barclays’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Barclays’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-300,000	Closed	-$522K	–	7619
2018 Q2	$522K	Sell	300,000 -215,000	-42%	-$372K	﹤0.01%	3908
2018 Q1	$942K	Buy	+515,000	New	+$1.09M	﹤0.01%	3291
2015 Q2	–	Sell	-210,000	Closed	-$840K	–	7327
2015 Q1	$840K	Buy	+210,000	New	+$683K	﹤0.01%	3134

Other funds holding SGYP

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Barclays's SGYP Position: Q1 2019 in Review

Barclays sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 25,084 shares — an estimated $3K sold.

Barclays first reported a position in SGYP in Q2 2013 and held it in 22 quarters. The position peaked at $1.11M in Q1 2018. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.

Barclays reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
Barclays sold 25,084 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $3K.
Barclays first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 22 quarters.
Barclays's Synergy Pharmaceuticals, Inc Common Stock position peaked at $1.11M in Q1 2018.
12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.

Based on Barclays's 13F filing for Q1 2019, filed 15 May 2019.